Loading
A phase 2 trial of Vididencel run by Mendus, of unknown status on the registry.
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia is a phase 2 interventional study registered as NCT03697707 by Mendus, with 20 participants planned, started 2018-10-15. Conditions recorded: Acute Myeloid Leukemia in Remission. Interventions recorded: DCP-001.
Shares Vididencel, Mendus, Acute myeloid leukaemia and the tag pipeline.
Shares Vididencel, Mendus and the tag pipeline.
Shares Vididencel, Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/